Bellerophon Therapeutics (NASDAQ:BLPH) Posts Quarterly Earnings Results

Bellerophon Therapeutics (NASDAQ:BLPH) posted its quarterly earnings results on Thursday. The biotechnology company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.01, Fidelity Earnings reports.

Shares of NASDAQ BLPH traded up $0.03 during mid-day trading on Friday, hitting $0.68. The stock had a trading volume of 179,111 shares, compared to its average volume of 164,479. The company has a current ratio of 2.99, a quick ratio of 2.99 and a debt-to-equity ratio of 0.18. Bellerophon Therapeutics has a 1 year low of $0.53 and a 1 year high of $1.33. The business’s 50 day moving average price is $0.64. The stock has a market capitalization of $44.79 million, a price-to-earnings ratio of -2.00 and a beta of -0.04.

Several research analysts have commented on the stock. Maxim Group reissued a “buy” rating and set a $2.00 price target on shares of Bellerophon Therapeutics in a research note on Friday. ValuEngine raised shares of Bellerophon Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 1st. Finally, Zacks Investment Research raised shares of Bellerophon Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a research note on Wednesday, May 15th.

In other news, Director Theodore T. Wang bought 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 12th. The shares were bought at an average cost of $0.64 per share, with a total value of $32,000.00. Following the completion of the purchase, the director now directly owns 584,479 shares in the company, valued at $374,066.56. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last ninety days, insiders purchased 75,000 shares of company stock worth $47,200. 53.10% of the stock is owned by insiders.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM.

Recommended Story: How mutual funds make money

Earnings History for Bellerophon Therapeutics (NASDAQ:BLPH)

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with's FREE daily email newsletter.